The global diabetes model: user friendly version 3.0
- PMID: 11080561
- DOI: 10.1016/s0168-8227(00)00215-1
The global diabetes model: user friendly version 3.0
Abstract
The attributes of Release 3.0 of the user friendly version (UFV) of the global diabetes model (GDM) are described and documented in detail. The GDM is a continuous, stochastic microsimulation model of type 2 diabetes. Suitable for predicting the medical futures of both individuals with diabetes and representative diabetic populations, the GDM predicts medical events (complications of diabetes), survival, utilities, and medical care costs. Incidence rate functions for microvascular and macrovascular complications are based on a combination of published studies and analyses of data describing diabetic members of Kaiser Permanente Northwest Region, a non-profit group-model health maintenance organization. Active risk factors include average blood glucose (HbAlc), systolic blood pressure (SBP), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides, smoking status, and use of prophylactic aspirin. Events predicted include diabetic eye disease, diabetic nephropathy, peripheral neuropathy amputation, myocardial infarction, stroke, peripheral artery disease, congestive heart failure, coronary artery surgery, coronary angioplasty, and death.
Similar articles
-
The Mt. Hood challenge: cross-testing two diabetes simulation models.Diabetes Res Clin Pract. 2000 Nov;50 Suppl 3:S57-64. doi: 10.1016/s0168-8227(00)00217-5. Diabetes Res Clin Pract. 2000. PMID: 11080563
-
Diabetic dyslipidemia.Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. doi: 10.1016/s0002-9149(98)00848-0. Am J Cardiol. 1998. PMID: 9915665 Review.
-
5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.Circulation. 1990 Jul;82(1):27-36. doi: 10.1161/01.cir.82.1.27. Circulation. 1990. PMID: 2194696
-
Concomitant macro and microvascular complications in diabetic nephropathy.Saudi J Kidney Dis Transpl. 2009 May;20(3):402-9. Saudi J Kidney Dis Transpl. 2009. PMID: 19414942
-
Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study.Metabolism. 2003 Aug;52(8 Suppl 1):19-23. doi: 10.1016/s0026-0495(03)00213-0. Metabolism. 2003. PMID: 12939735 Review.
Cited by
-
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation.Diabetes Technol Ther. 2015 Oct;17(10):701-11. doi: 10.1089/dia.2014.0304. Epub 2015 Jul 29. Diabetes Technol Ther. 2015. PMID: 26222704 Free PMC article.
-
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.Pharmacoeconomics. 2002;20 Suppl 1:31-42. doi: 10.2165/00019053-200220001-00004. Pharmacoeconomics. 2002. PMID: 12036382
-
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process.Pharmacoeconomics. 2022 Nov;40(11):1015-1032. doi: 10.1007/s40273-022-01185-z. Epub 2022 Sep 14. Pharmacoeconomics. 2022. PMID: 36100825 Free PMC article. Review.
-
Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.Diabetes Ther. 2020 Nov;11(11):2657-2676. doi: 10.1007/s13300-020-00923-w. Epub 2020 Sep 15. Diabetes Ther. 2020. PMID: 32930969 Free PMC article.
-
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.Pharmacoeconomics. 2006;24 Suppl 1:49-59. doi: 10.2165/00019053-200624001-00005. Pharmacoeconomics. 2006. PMID: 16800162 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical